FDA-cleared profile

QFR (3.0)

QFR Solutions bv

QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.
FDA source Exact FDA submission Checked 2026-09-07
Intended users
Interventional cardiologists or researchers who review coronary angiography; responsible clinicians must review and may correct analysis inputs and contours.
FDA source Exact FDA submission Checked 2026-09-07
Care setting and population
Cardiac catheterization laboratory or image-review workstation supporting coronary angiography analysis.
FDA source Exact FDA submission Checked 2026-09-07
Workflow role
Post-processing decision support for quantitative coronary vessel and lesion assessment and pressure-drop estimation; it supplements, rather than replaces, angiographic and clinical judgment.
FDA source Exact FDA submission Checked 2026-09-07
Required input
Coronary X-ray angiography DICOM acquisitions from a monoplane or biplane system, with two suitable projections separated by at least 25 degrees and adequate calibration and image quality.
FDA source Exact FDA submission Checked 2026-09-07
Output and human action
Three-dimensional reconstructed coronary vessels, vessel and lesion dimensions, quantitative flow ratio/pressure-drop values, analysis snapshots, and a report containing patient, acquisition, and analysis information.
FDA source Exact FDA submission Checked 2026-09-07
Limitations
The analysis requires suitable paired angiographic views, calibration, at least five frames, and adequate vessel visibility. The user must review and correct contours or reference diameter when needed; incorrect contours or reference diameter can produce an incorrect QFR result. The output is not a replacement for clinical judgment.
FDA source Exact FDA submission Checked 2026-09-07

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243769
FDA source Exact FDA submission Checked 2026-08-31
Modality
Fluoroscopy/Angiography
FDA source Exact FDA submission Checked 2026-09-07
Anatomy
Heart/Cardiovascular
FDA source Exact FDA submission Checked 2026-09-07
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-04-04
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The exact software imports coronary XA DICOM studies and can exchange studies and reports with PACS through DICOM services; local modality, PACS, worklist, export, and report routing require acceptance testing.
FDA source Exact FDA submission Checked 2026-09-07
Deployment and data flow
The exact FDA packet and QFR manual describe a server installed in the organization network or cathlab/hospital server room, accessed through a web browser; the manual states the QFR server is not cloud or internet hosted for the reviewed version.
FDA source Exact FDA submission Checked 2026-09-07
Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

The reviewed packet and manual describe local deployment, user roles, and audit-trail functions but do not establish a current scoped security attestation, encryption configuration, retention, vulnerability management, or incident response for the installed K243769 release.

Training and support
Use requires trained interventional cardiologist or researcher review of projection selection, calibration, vessel and lesion contours, reference diameter, QFR result, and report; local competency and escalation procedures remain site responsibilities.
FDA source Exact FDA submission Checked 2026-09-07
Monitoring and change control
Monitor projection and calibration eligibility, contour edits, completed versus no-result analyses, report and DICOM delivery, reader overrides, user/audit events, downtime, updates, complaints, and recalls by exact K243769 release.
FDA source Exact FDA submission Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and manual; it is not a claimed vendor monitoring service.

Local server deployment

The QFR manual places the QFR server in the organization network and states it is not cloud or internet hosted for the reviewed version; access is through a web browser and local DICOM connections must be configured.

product family · checked 2026-09-07

Manual version 3.0.36.6 was reviewed; confirm that the installed K243769 release has the same deployment behavior.

DICOM and report workflow

The manual documents DICOM connection administration, PACS export, audit trail, user roles, and report archiving when configured; test modality import, projection selection, export, report delivery, and failure recovery locally.

product family · checked 2026-09-07

Input-quality gate

The reviewed manual requires XA studies with grayscale square pixels, fixed angulation, calibration, at least five frames, and two projections with at least 25 degrees between angles; invalid or incomplete acquisitions may block or distort analysis.

product family · checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K243769 FDA evidence is a regulatory image-analysis validation for QFR 3.0; no independent paper or trial was promoted in this timeboxed review.
FDA source Exact FDA submission Checked 2026-09-07
Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

RCA vessel classification correct

96 percent

Correct vessel classification for RCA in Regulatory QFR image-analysis validation cases.

Tested version: QFR 3.0 configuration described in K243769

LAD vessel classification correct

88 percent

Correct vessel classification for LAD in Regulatory QFR image-analysis validation cases.

Tested version: QFR 3.0 configuration described in K243769

LCX vessel classification correct

78 percent

Correct vessel classification for LCX in Regulatory QFR image-analysis validation cases.

Tested version: QFR 3.0 configuration described in K243769

Start/end detection correct

77 percent

Correct automatic start and end point detection in Regulatory QFR image-analysis validation cases.

Tested version: QFR 3.0 configuration described in K243769

K243769 QFR 3.0 regulatory image-analysis validation

Retrospective regulatory validation of vessel classification, endpoint detection, and QFR image-analysis outputs on coronary X-ray angiography. · Coronary angiography studies representative of intended interventional cardiology or research use; the reviewed FDA summary reports endpoint percentages without a single overall sample count.

exact submission · Tested version: QFR 3.0 configuration described in K243769 · Sponsor or vendor study

K243769

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

No public list price or contract unit for the exact K243769 configuration was established in the reviewed official sources.

Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-09-07

CMS plaque-policy review was not applied to this angiography dossier; no product-specific coverage determination is made.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K243769. This does not establish absence of family, later-version, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-07

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-07.

Alternatives

Related tools to compare

FDA-cleared K252500

CARA System

Cara Medical, Ltd.

CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying...

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20
FDA-cleared K243884

TAVIPILOT

Caranx Medical

TAVIPILOT detects, tracks, and marks the non-coronary cusp and prosthetic valve on live fluoroscopy during specified adult femoral TAVR or TAVI procedures under physician control.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2025-07-07
FDA-cleared K252099

Trinias

Shimadzu Corporation

Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational,...

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24